EG23858A - Drug combination - Google Patents

Drug combination

Info

Publication number
EG23858A
EG23858A EG20000124A EG20000124A EG23858A EG 23858 A EG23858 A EG 23858A EG 20000124 A EG20000124 A EG 20000124A EG 20000124 A EG20000124 A EG 20000124A EG 23858 A EG23858 A EG 23858A
Authority
EG
Egypt
Prior art keywords
drug combination
drug
combination
Prior art date
Application number
EG20000124A
Other languages
English (en)
Inventor
Ali Raza
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EG23858(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9902593.4A external-priority patent/GB9902593D0/en
Priority claimed from GBGB9921064.3A external-priority patent/GB9921064D0/en
Priority claimed from GBGB9921063.5A external-priority patent/GB9921063D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Application granted granted Critical
Publication of EG23858A publication Critical patent/EG23858A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EG20000124A 1999-02-06 2000-02-22 Drug combination EG23858A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9902593.4A GB9902593D0 (en) 1999-02-06 1999-02-06 Drug combinations
GBGB9921064.3A GB9921064D0 (en) 1999-09-08 1999-09-08 Drug combination
GBGB9921063.5A GB9921063D0 (en) 1999-09-08 1999-09-08 Therapy

Publications (1)

Publication Number Publication Date
EG23858A true EG23858A (en) 2007-11-18

Family

ID=27269637

Family Applications (1)

Application Number Title Priority Date Filing Date
EG20000124A EG23858A (en) 1999-02-06 2000-02-22 Drug combination

Country Status (28)

Country Link
US (3) US6982157B1 (enExample)
EP (1) EP1185274B1 (enExample)
JP (2) JP2002536331A (enExample)
KR (2) KR20060117381A (enExample)
CN (1) CN1165310C (enExample)
AR (1) AR029333A1 (enExample)
AT (1) ATE282415T1 (enExample)
AU (1) AU767304B2 (enExample)
BR (1) BR0007999A (enExample)
CA (1) CA2358632C (enExample)
CZ (1) CZ301296B6 (enExample)
DE (1) DE60015965T2 (enExample)
EE (1) EE04929B1 (enExample)
EG (1) EG23858A (enExample)
ES (1) ES2232418T3 (enExample)
GB (1) GB0000710D0 (enExample)
ID (1) ID30485A (enExample)
IL (1) IL144715A0 (enExample)
IS (1) IS2337B (enExample)
MX (1) MXPA01007905A (enExample)
MY (1) MY130606A (enExample)
NO (1) NO320745B1 (enExample)
NZ (1) NZ512982A (enExample)
PL (1) PL198034B1 (enExample)
PT (1) PT1185274E (enExample)
TR (1) TR200102228T2 (enExample)
TW (1) TWI282738B (enExample)
WO (1) WO2000045817A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
DE19944803A1 (de) * 1999-09-20 2001-03-29 Bayer Ag Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
BRPI0206641B8 (pt) 2001-01-26 2021-05-25 Merck Sharp & Dohme uso de um inibidor da absorção de esteróis
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
SK288217B6 (sk) 2001-01-26 2014-08-05 Merck Sharp & Dohme Corp. Zmes, terapeutická kombinácia, farmaceutický prostriedok a ich použitie
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
DE60216300T2 (de) 2001-09-21 2007-06-28 Schering Corp. Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
AU2003291719A1 (en) 2002-11-06 2004-06-03 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
ES2311806T3 (es) 2003-03-07 2009-02-16 Schering Corporation Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
CA2517573C (en) 2003-03-07 2011-12-06 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
CN1756756A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
US9173847B2 (en) 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
JP5069001B2 (ja) 2003-10-10 2012-11-07 ベロクシス ファーマシューティカルズ エー／エス フィブラートを含む固体投与形態
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AU2005271413A1 (en) 2004-08-06 2006-02-16 Transform Pharmaceuticals, Inc. Novel statin pharmaceutical compositions and related methods of treatment
EP1948600B1 (en) * 2005-07-05 2014-04-16 The President & Fellows Of Harvard College Liver targeted conjugates
EP1968593B1 (en) * 2005-12-20 2017-08-23 LEK Pharmaceuticals d.d. Pharmaceutical composition comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl-(3r,5s)-3,5-dihydroxyhept-6-enoic acid
US20080109252A1 (en) * 2006-11-08 2008-05-08 Lafountain Andrea Predicting patient compliance with medical treatment
US20120130202A1 (en) * 2010-11-24 2012-05-24 Fujitsu Limited Diagnosis and Monitoring of Musculoskeletal Pathologies
CN112955965B (zh) * 2018-06-14 2024-04-09 阿斯利康(英国)有限公司 使用二氢吡啶类钙通道阻断剂医药组合物降低血压的方法
US20220273652A1 (en) 2019-07-31 2022-09-01 Intas Pharmaceuticals Ltd. Pharmaceutical composition comprising hmg-coa reductase inhibitors and fenofibrate
WO2024223797A1 (en) 2023-04-28 2024-10-31 Institut National de la Santé et de la Recherche Médicale Use of cyp3a4 inhibitors for the treatment of hepatitis d virus (hdv) infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
DK0521417T3 (da) * 1991-07-02 1995-03-27 Benckiser Gmbh Joh A Sammenklappelig forrådsflaske
JP3852621B2 (ja) * 1992-01-21 2006-12-06 あすか製薬株式会社 血管内皮細胞機能改善剤
FR2730231B1 (fr) * 1995-02-02 1997-04-04 Fournier Sca Lab Association de fenofibrate et de vitamine e, utilisation en therapeutique
KR20010031501A (ko) * 1997-10-31 2001-04-16 추후제출 5-알파 환원효소 활성을 조절하는 방법 및 조성물

Also Published As

Publication number Publication date
CA2358632A1 (en) 2000-08-10
TR200102228T2 (tr) 2002-03-21
IS6009A (is) 2001-07-17
ID30485A (id) 2001-12-13
IL144715A0 (en) 2002-06-30
KR20060117381A (ko) 2006-11-16
BR0007999A (pt) 2001-11-06
CN1338936A (zh) 2002-03-06
DE60015965D1 (de) 2004-12-23
MXPA01007905A (es) 2003-06-04
TWI282738B (en) 2007-06-21
GB0000710D0 (en) 2000-03-08
PL364780A1 (en) 2004-12-13
US20090042911A1 (en) 2009-02-12
EE04929B1 (et) 2007-12-17
NO320745B1 (no) 2006-01-23
AR029333A1 (es) 2003-06-25
US20060040969A1 (en) 2006-02-23
NZ512982A (en) 2003-08-29
JP2007277267A (ja) 2007-10-25
WO2000045817A1 (en) 2000-08-10
KR20010101790A (ko) 2001-11-14
NO20013811L (no) 2001-10-02
ATE282415T1 (de) 2004-12-15
PL198034B1 (pl) 2008-05-30
CN1165310C (zh) 2004-09-08
NO20013811D0 (no) 2001-08-03
JP2002536331A (ja) 2002-10-29
CA2358632C (en) 2008-10-28
MY130606A (en) 2007-07-31
EE200100406A (et) 2002-10-15
CZ20012844A3 (cs) 2001-11-14
HK1041817A1 (en) 2002-07-26
CZ301296B6 (cs) 2010-01-06
PT1185274E (pt) 2005-03-31
ES2232418T3 (es) 2005-06-01
EP1185274B1 (en) 2004-11-17
EP1185274A1 (en) 2002-03-13
US6982157B1 (en) 2006-01-03
AU767304B2 (en) 2003-11-06
DE60015965T2 (de) 2006-01-05
AU2121800A (en) 2000-08-25
IS2337B (is) 2008-02-15

Similar Documents

Publication Publication Date Title
EG23858A (en) Drug combination
PL351686A1 (en) Novel pharmaceutical
HUP0203585A3 (en) Pharmaceutical combinations
EG23937A (en) Novel pharmaceutical
GB9930079D0 (en) Medicaments
GB9930071D0 (en) Medicaments
GB9911802D0 (en) Therapeutic combination
GB9928607D0 (en) Syringes
GB9911803D0 (en) Therapeutic combination
PL351135A1 (en) Novel pharmaceutical
GB9911804D0 (en) Therapeutic combination
EG23946A (en) Novel pharmaceutical
IL146341A0 (en) Pharmaceutical complex
GB9930083D0 (en) Medicaments
GB9924990D0 (en) Medicaments
GB9929040D0 (en) Medicaments
GB9930082D0 (en) Medicaments
GB9904935D0 (en) Medicaments
GB9923933D0 (en) Novel pharmaceutical
GB9921764D0 (en) Syringe
GB9921064D0 (en) Drug combination
GB9929039D0 (en) Medicaments
GB9902593D0 (en) Drug combinations
GB9923934D0 (en) Novel pharmaceutical
GB9911499D0 (en) Medicament